DeutschNewstral
Article
bizjournals.com on 2015-03-09 14:43
Durham cancer drug developer sees shares pop 35% on FDA designation
Related news
- Durham-based cancer drug developer sees shares tumble one day after big popbizjournals.com
- With eyes on FDA, Durham drug developer tests drug in late-stage trialbizjournals.com
- Durham drug developer gets FDA cash to work on orphan disease drugbizjournals.com
- Durham pharma gets another boost with FDA fast-track designationbizjournals.com
- Fed designation could give Durham drug developer lots of perksbizjournals.com
- Special FDA designation puts more wind behind BioCryst's sailsbizjournals.com
- IGenprex up by 130% after receiving FDA fast track designationinvezz.com
- Portland biotech company gains FDA Fast Track designationbizjournals.com
- MAkari Therapeutics' stock rockets on heavy volume after FDA grants nomacopan 'Fast Track' designationmarketwatch.com
- MAkari Therapeutics shares soar 13% premarket after FDA grants Orphan Drug designation to nomacopanmarketwatch.com
- Durham drugmaker preps for commercialization as it awaits FDA approvalbizjournals.com
- Durham drugmaker secures its first FDA approval, pivots to commercializationbizjournals.com
- Durham pharma scores FDA, CE approvals; readies for product launchbizjournals.com
- Raleigh drug developer sees shares soar on good news from FDAbizjournals.com
- With FDA approval, Raleigh's BioDelivery sees 10% stock bouncebizjournals.com
Artiva Biotherapeutics Receives FDA Fast Track Designation for AlloNK in Lupus Nephritisjdsupra.com- DFDA grants generic therapy designation for Purdue Pharma’s opioid overdose treatmentdailyvoiceplus.com
- FDA gives Biogen the nod to manufacture MS drug in Durhambizjournals.com
- Durham pharma receives FDA approvalbizjournals.com
Loxo Oncology treatment earns FDA special designationwestfaironline.com